Anatara Lifesciences transitions gut health focus from animals to humans - Steve Lydeamore, CEO, Anatara Lifesciences Ltd 00:00:00
Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steven Lydeamore speaks to Proactive Investors about the healthcare company's renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).